# Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease

> **NCT02244541** · PHASE2 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 32 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ANAVEX2-73 Oral
- **DRUG:** ANAVEX2-73 Intravenous
- **DRUG:** ANAVEX2-73 Oral
- **DRUG:** ANAVEX2-73 Oral

## Key facts

- **NCT ID:** NCT02244541
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-11
- **Final completion:** 2016-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244541, "Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02244541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*